Everolimus – a new approach in the treatment of renal cell carcinoma by Anandappa, G et al.
© 2010 Anandappa et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2010:2 61–70
Cancer Management and Research
61
R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
everolimus – a new approach in the treatment  
of renal cell carcinoma
G Anandappa  
Ae Hollingdale  
TG eisen
Department of Oncology, Cambridge 
University Hospitals NHS Foundation 
Trust, Cambridge, UK
Correspondence: T eisen  
Box 193 (R4),   Addenbrooke’s Hospital, 
Cambridge CB2 0QQ, UK  
Tel +44 (0) 1223 769312  
Fax +44 (0) 1223 769313  
email tim.eisen@medschl.cam.ac.uk
Abstract: With the increasing understanding of the biology of the disease and the development 
of targeted therapy, there has been a paradigm shift in the treatment of clear cell metastatic renal 
cell carcinoma (mRCC). Traditionally patients with metastatic RCC have been treated with 
immunotherapy which has limited efficacy. The multikinase inhibitors sunitinib, sorafenib and 
pazopanib, the VEGF antibody bevacizumab in combination with interferon and the mTOR 
inhibitor temsirolimus have all been shown to prolong progression-free survival in phase 
III studies. Here we review another mTOR inhibitor, everolimus (Afinitor®; Novartis, USA) 
which was approved in March 2009 by the US FDA for treatment of targeted-therapy refrac-
tory metastatic renal cell cancer. The phase III study of everolimus (the RECORD study) was 
terminated early after a significant difference in efficacy was noted in the treatment arm with 
everolimus (progression-free survival of 4.0 months in patients on the treatment arm vs 1.9 
months in the placebo arm). The most common adverse events were stomatitis, pneumonitis, 
fatigue and infections. We review Phase I–III data with a particular emphasis on safety data 
and patient focused outcomes.
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Introduction to the management issues  
in the treatment of metastatic RCC
Renal cell carcinoma (RCC) accounts for 2% to 3% of malignant tumors of adults. With 
a world-wide incidence of 200,000 cases and 102,000 deaths per year, it remains the 
seventh most common cancer in men and the ninth most common cancer in women.1 
RCC usually presents in the sixth or seventh decade, with a male:female ratio of 1.6:1.2 
Risk factors include von Hippel-Lindau syndrome, autosomal dominant polycystic 
kidney disease, renal dialysis or transplant, obesity and smoking.3 Patients can present 
with a wide variety of symptoms; the classical triad of loin pain, painless hematuria 
and a mass in the flank, paraneoplastic phenomena such as fever, anorexia or symptoms 
of hypercalcemia, or as an incidental finding due to the increased use of imaging tech-
nologies. At presentation, disease is localized in almost 60% of patients, with locally 
advanced disease in 18% and metastatic disease in 19% of cases.4 The most common 
site for metastasis is to the lungs (75%); other sites include soft tissue (36%), bone 
(20%), liver (18%) and brain (8%).5 Of the patients who present with localized disease 
a further third of these will go on to develop metastases in the future.
Surgery remains the main stay of treatment for non-metastatic disease; with 
options of partial nephrectomy, and radical nephrectomy for large tumors. Systemic 
therapy is the mainstay of treatment for patients with metastatic disease. Aldesleukin Cancer Management and Research 2010:2 62
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(recombinant interleukin-2) and interferon-alfa have been 
the standard of care for patients with metastatic renal cell 
carcinoma until recently. Despite the use of these agents 
for more than 20 years, the effectiveness of these two drugs 
is still controversial. The greatest benefit is achieved when 
applied to a very select group of patients with good prognosis, 
potentially achieving durable remissions, albeit in a small 
minority of patients.6
Identification of the causative biological pathways and 
development of targeted therapy has been crucial in caus-
ing a paradigm shift in the treatment of metastatic clear cell 
renal cell carcinoma. Clear cell is the commonest variant 
accounting for 75% of renal cell carcinomas. Other variants 
include nonclear cell types such as papillary (10% to 15%), 
chromophobe and sarcomatoid. The pathogenesis of clear cell 
RCC is associated with loss of function of von Hippel-Lindau 
(VHL) gene and overproduction of the hypoxia-inducible 
factor (HIF). The VHL gene is mutated in ≈ 70% of patients 
with RCC; additionally, VHL is silenced in another 20% of 
patients.7
Loss of VHL gene product (pVHL) upregulates HIF-α 
expression which has been strongly implicated in RCC. 
HIF-α dimerizes with HIF-β and results in the transcription 
of genes that regulate angiogenesis such as vascular endo-
thelial growth factor (VEGF), platelet-derived growth fac-
tor (PDGF) and transforming growth factor beta (TGFβ).8,9 
VEGF and other factors induced by HIF-α are thought to be 
the key drivers of tumor angiogenesis, permitting the growth 
and progression of renal cancers.10,11 Activation of mTOR 
(mammalian target of rapamycin) also leads to increased 
expression of HIF-1α in clear cell renal cell cancer.12,13 
VEGFR/PDGFR inhibiting drugs and the mTOR-inhibiting 
drugs are now the targeted therapies approved for use in 
clinical practice.
The mTOR pathway
Activation of mTOR promotes the proliferation and survival 
of tumor cells. The mTOR kinase also controls angiogenic 
pathways via hypoxia-inducible factor-1α (HIF-1α), vascular 
endothelial growth factor (VEGF) and via endothelial and 
smooth muscle cell proliferation which have been implicated 
in the etiology of clear cell renal cell carcinoma.14,15
Rapalogs have long been known to inhibit the mTOR 
pathway. The natural product rapamycin binds to an intracel-
lular protein known as FK506-binding protein 12 (FKBP12) 
and the resultant protein-drug complex inhibits the kinase 
activity of mTOR.16 mTOR is a highly conserved intracellular 
multi functional signal transduction serine-threonine kinase, 
and is a key regulatory protein in cancer that recognizes 
stress signals (eg, nutrient and energy depletion, oxidative 
or hypoxic stress, and proliferative and survival signals) via 
the phosphotidylinositol 3 kinase-protein kinase (PI3K-AKT) 
pathway. The PI3K-AKT-mTOR pathway is dys-regulated 
in many cancers.16 In response to extracellular stimuli, PI3K 
phosphorylates the 3´-hydroxyl of phosphotidylinositol-4, 
5-bisphosphate (PIP2) to generate phosphotidylinositol-3, 4, 
5-triphosphate (PIP3). The formation of PIP3 leads to mem-
brane localization and activation of phosphotidylinositol-
dependent kinase-1 (PDK1) and AKT.17 The tumor suppressor 
phosphatase PTEN (phosphatase tensin homologue deleted 
on chromosome 10) dephosphorylates PIP3 reversing the 
action of PI3K. Activated AKT phosphorylates and inhibits 
tuberous sclerosis complex (TSC) and removes its inhibitory 
effect on mTOR.18,19
mTOR exists in two complexes called mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), that differ in 
subunit composition and sensitivity to rapamycin.20 mTORC1 
is highly sensitive to rapamycin whereas mTORC2 is rela-
tively insensitive to rapamycin.21 HIF-1α expression depends 
on mTORC1 and mTORC2 expression whilst HIF-2α 
depends on mTORC2.22
The mechanism of action of the mTOR inhibitors is quite 
distinct from those of drugs inhibiting VEGFR/PDGFR. 
Their unique action is attributed to their effect directly on the 
tumor cells themselves, in part due to HIF downregulation, 
and on tumor endothelial cells by blocking proliferation and 
survival signals downstream of the VEGF receptor.23–25 One 
study has also shown that the benefits of mTOR inhibition 
may be greater in papillary renal carcinoma than in clear 
cell carcinoma; papillary subtype accounting for 10% to 
15% of renal cell cancers.26 This is postulated to be due to 
HIF upregulation which is noted in patients with papillary 
renal cell carcinoma associated with fumarate–hydratase 
mutations.27
mTOR-inhibiting drugs in renal cancer
Temsirolimus (Torisel®; Wyeth, USA), was the first mTOR 
inhibitor to be approved for treatment of RCC. A randomized 
phase III trial done in patients with metastatic carcinoma and 
three or more of the following adverse risk features: Karnof-
sky performance status less than 80%, lactate dehydrogenase 
greater than 1.5-fold laboratory upper limit of normal, hemo-
globin less than laboratory lower limit of normal, corrected 
serum calcium concentration greater than 2.5 mmol/L, time 
from diagnosis of renal cell carcinoma to start of treatment 
of less than 1 year and at least 3 metastatic sites.28,29 A total Cancer Management and Research 2010:2 63
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of 626 patients were randomly assigned to temsirolimus 
25 mg per week intravenously versus interferon alone versus 
temsirolimus 15 mg per week intravenously plus interferon. 
Approximately 80% of the patients in each group had a Kar-
nofsky performance score of 60 or 70. Clear cell carcinoma 
was the histology of the tumor in approximately 80% of the 
patients, two-thirds of the patients had prior nephrectomy and 
approximately 80% had received a diagnosis of metastatic 
disease within 12 months before enrolment. Patients with 
advanced renal cell carcinoma and a poor prognosis treated 
with temsirolimus had a longer overall survival than those on 
interferon monotherapy (10.9 months vs 7.3 months, hazard 
ratio for death 0.73, 95% confidence interval [CI] 0.58 to 
0.92; P = 0.008). A benefit in progression-free survival (PFS) 
was noted for patients treated with temsirolimus alone versus 
interferon (median 3.8 months vs 1.9 months; P  0.0001). 
No survival advantage occurred in the combination treatment 
arm compared with interferon alone. Exploratory subgroup 
analysis of the effects of temsirolimus alone on overall 
survival was consistent across prespecified factors with the 
exception of age and serum lactate dehydrogenase levels. 
The study also revealed that the benefit of mTOR inhibition 
might be greater in papillary renal carcinoma than in clear 
cell carcinoma.17
Everolimus (Afinitor®; RAD001; Novartis, USA) is 
an orally bioavailable mTOR inhibitor that binds with 
high affinity to its intracellular receptor FKBP12, at the 
same point in the mTOR pathway as temosirolimus. The 
everolimus-FKBP12 complex binds to mTOR and reduces 
the activity of the downstream effectors S6 ribosomal 
protein kinase (S6K1) and translational repressor protein 
eukaryotic elongation factor 4E-binding protein (4EBP).19 
eIF-4F activation results in the translation of a subset of 
capped mRNA containing highly structured 5′-untranslated 
regions and encoding proteins involved in G1- to S-phase 
progression.30 Mitogen-induced activation of the S6K1 is 
dependent on mTOR function and has been implicated in the 
translational regulation of mRNAs possessing a 5′-terminal 
oligopyrimidine tract.31 5′-terminal oligopyrimidine tract 
mRNAs are characterized by a stretch of 4 to 14 pyrimidines 
located at their extreme 5′ terminus and typically encode 
ribosomal proteins as well as components of the translational 
machinery. Activation of S6K1 itself is also tightly regulated 
by hierarchical phosphorylation events, which are dependent 
on the activation of various signal transduction pathways and 
culminate in the phosphorylation of the rapamycin-sensitive 
site Thr389.32,33 Hence, reductions in S6 phosphorylation by 
everolimus is expected to parallel S6K1 inactivation. Preclini-
cal ex-vivo experiments have demonstrated that peripheral 
blood mononuclear cell (PBMC)-derived 4E-BP1 was unaf-
fected by a suboptimal RAD001 dose despite transient effects 
on S6K1 activity, suggesting that S6K1 is a more sensitive 
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Figure 1 The mTOR pathway.
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marker of everolimus exposure in PBMCs than 4E-BP1. All 
doses of RAD001 evaluated elicited a dramatic inhibition of 
PBMC-derived S6K1 after 24 hours and increasing RAD001 
concentrations led to almost complete inactivation of S6K1. 
The rate at which S6K1 activity subsequently recovered dif-
fered, with everolimus doses that were efficacious with weekly 
schedules causing more profound long-term effects on S6K1 
activity (7 days). Unlike 4E-BP1 phosphorylation, S6K1 
activity can be measured in human PBMCs making it a good 
pharmacodynamic biomarker of everolimus activity.34
Clinical studies
Phase i studies
A 2-part dose escalation study in advanced cancer 
patients was conducted administering oral everolimus 5 to 
30 mg/week during part 1, with pharmacokinetic (PK) and 
pharmacodynamic (PD) studies. The patients had advanced 
solid tumours refractory to standard therapy, World Health 
Organization performance status of 0, 1 or 2, an estimated 
life expectancy of at least 3 months, adequate bone marrow 
function, and normal liver and renal function. During part 
2 of the study, 50 and 70 mg weekly and daily dosing of 
5 and 10 mg was administered. In part 1 of the study toxic-
ity, antitumor activity, PK, and the relationship of dose to 
inhibition of S6K1 in PBMCs were evaluated with weekly 
oral everolimus doses of 5, 10, 20 and 30 mg. Part 1 lasted 
for 4 weeks, with a drug-free week in week 5. PK and PD 
sampling was performed pre dose for the first 4 weeks, and in 
week 5. Part 2 of the study investigated higher weekly doses 
(50 and 70 mg) and daily administration (5 and 10 mg) for 
evaluation of safety data at higher weekly levels.35 The end 
points of the study were weekly assessments for toxicity and 
standard laboratory panels for 5 weeks and then monthly, 
and imaging assessed by RECIST criteria every 2 months. 
92 patients with advanced solid tumours, including 10 renal 
cell carcinoma patients were part of the study. In total 18 
were treated weekly in part 1, and in part 2, 37 were treated 
weekly, and 37 were treated daily.
Safety data
The majority of serious toxicities (18/19 of grade 3 or 4) 
were seen at higher doses of everolimus (10 mg daily or 
70 mg weekly). No information about correlation of tox-
icity to blood levels or surrogate markers of everolimus 
activity in individual patients was included in the paper, 
although appeared to occur if the weekly area under the 
curve (AUC) is around 3500 ng.h/mL, corresponding to 
the higher weekly and daily dosage regimes. Dose-limiting 
toxicities (CTC V2.0 grade 3 or higher) at 70 mg weekly 
included stomatitis (2 at 10mg daily), hyperglycemia (2 at 
10 mg daily and 1 at 70 mg weekly), fatigue (1 at 70 mg 
weekly), dyspnea (1 at 10 mg daily), pneumonia (10 mg 
weekly), thrombocytopenia (2 at 10 mg daily, 1 at 70 mg 
weekly), hypertriglyceridemia (1 at 70 mg weekly, 1 at 
10 mg daily), anorexia (2 at 10 mg daily), pneumonitis (1 
at 70 mg weekly), erythematous rash (1 at 10 mg daily), 
nausea (1 at 10 mg daily), melena (1 at 70 mg weekly), 
epistaxis (1 at 10 mg daily). Five patients had severe toxic-
ity that was suspected to be drug related which included 
hemorrhagic gastritis, recurrent epistaxis, bronchiolitis 
obliterans organizing pneumonia, pneumonia associated 
with lymphopenia and fatigue with stomatitis.35
Pharmacokinetics
Absorption
In patients with advanced solid tumors, peak steady state 
concentrations (Cmax) are achieved at a median time of 1 hour 
after daily administration of 5 mg and 10 mg doses under 
fasting conditions. In healthy subjects high-fat meals reduced 
systemic exposure to everolimus 10 mg (as measured by 
AUC) by 22% and light fat meals reduced AUC by 32%.36
Metabolism
Everolimus is extensively metabolized by CYP3A4 and PgP. 
Samples were assessable for full 24-hour PK profiles in 26 
of the 31 patients who received the weekly regimen and in 
10 of the daily regimen patients.
Using the weekly regimen, stable predose serum trough 
concentration levels from weeks 2 to 5 indicated minimal 
accumulation at all weekly dose levels, with steady-state 
achieved by week 2 of treatment. Dose normalization 
showed that serum steady state concentration increased in 
a roughly dose-proportional manner from 5 to 20 mg per 
week but increased less than proportionally at higher doses. 
The increase in AUC at steady state was dose proportional 
over the full dose range. Elimination half-life averaged 30 ± 
8 hours across all patients and was similar to that in healthy 
controls.
Daily regimen usage resulted in a steady state level 
within a week. Trough levels were stable thereafter, averaging 
5.4 ng/mL (5 mg/day dosing) and 13.2 ng/mL (10 mg/day 
dosing). Peak concentrations were achieved within 1 hour 
of daily dosing with one exception (6 hours). Both maxi-
mum serum concentration and AUC increased in a dose-
proportional manner. Plasma concentrations and levels of 
sustained S6K1 inhibition observed at 20 mg everolimus Cancer Management and Research 2010:2 65
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weekly and 5 mg daily correlate with those seen in preclini-
cal models resulting in antitumor activity.
Pharmacokinetic characteristics were consistent with 
those observed both in normal volunteers and in patients 
in the transplantation setting and with dose-proportional 
increases in AUC.35
elimination
No specific excretion studies have been undertaken in can-
cer patients; however, data are available from the studies 
in transplant patients. Following administration of a single 
labeled everolimus in conjunction with cyclosporine, 80% 
of the radioactivity was recovered from the feces, whilst 5% 
was excreted in the urine.
Special populations
Hepatic impairment: The average AUC of everolimus in 
8 subjects with moderate hepatic impairment (Child–Pugh 
class B) was twice that found in 8 subjects with normal 
hepatic function. AUC correlated positively with serum bili-
rubin concentration and prolongation of prothrombin time 
and negatively correlated with serum albumin concentra-
tion. The impact of severe hepatic impairment (Child–Pugh 
class C) on the pharmacokinetics of everolimus has not been 
assessed.
Renal impairment: No significant influence of creatinine 
clearance was detected in a population pharmacokinetic 
analysis of 170 patients.
Elderly patients: No significant influence of age (27 to 
85 years) on oral clearance was detected in a population 
pharmacokinetic analysis.36
Phase i tumor pharmacodynamic study
A Phase I study tumor pharmacodynamic study was con-
ducted in 55 patients with advanced solid tumors.37 Patients 
received everolimus in cohorts of 20, 50 and 70 mg weekly 
or 5 and 10 mg daily. Dose escalation was based on dose-
limiting toxicity (DLT) rate during the first 4-week period. 
Pre- and on-treatment steady-state tumor and skin biopsies 
were evaluated for total and phosphorylated (p) protein S6 
kinase 1, eukaryotic initiation factor 4E (eIF-4E) binding 
protein 1(4E-BP1), eukaryotic initiation factor 4G (eIF-4G), 
AKT and Ki-67 expression. Plasma trough levels of everoli-
mus were determined on a weekly basis before dosing dur-
ing the first 4 weeks. Dose related and schedule dependent 
inhibition of pS6 and peIF-4G occurred almost completely at 
10 mg/day and 50 mg/week. Also, pAKT was upregulated 
in 50% of untreated tumors. Clinical benefit was observed in 
four patients and DLT was seen in 5 patients and included 
stomatitis, neutropenia and hyperglycemia. The study recom-
mended a dosage of 10 mg per day or 50 mg per week.
Phase II studies
In a 2-stage, single-arm, phase II trial to determine the PFS 
of patients with metastatic clear cell RCC who had received 
1 prior therapy and had progressive, measurable metastatic 
disease, everolimus was given at a dose of 10 mg daily. Of 
41 enrolled patients, 39 were treated and evaluable for safety 
and 37 were evaluable for response. The median PFS was 
11.2 months and the median overall survival was 22.1 months. 
Partial responses were observed in 14% of patients, stable dis-
ease lasting for 3 months in 73% patients and stable disease 
lasting 6 months was reported in 57% of patients.38
Safety data
This study reported the adverse events shown in Table 1.
Another multicenter Phase II trial evaluated the efficacy 
and safety of a combination of bevacizumab 10 mg/kg every 
2 weeks and everolimus 10 mg daily in patients with meta-
static RCC. Patients with metastatic or unresectable locally 
recurrent clear cell RCC were enrolled and divided into 
2 groups: group A, no previous treatment with sorafenib or 
sunitinib; group B, previous treatment with sorafenib and/or 
sunitinib. 59 patients (30 group A, 29 group B) were enrolled 
into the study, 42 patients received at least 8 weeks of treat-
ment and were re-evaluated; 6 patients were unable to be 
evaluated due to toxicity, rapid progression or intercurrent 
Table 1 Laboratory abnormalities (incidence by NCi-CTCAe 
v3.0 grade, number in %) (n = 39 pts)
Event Grade 1 Grade 2 Grade 3
elevated alkaline phosphate 61.5 30.8 7.7
elevated alanine transaminase 35.9 20.5 10.3
Hyperglycemia 41.0 10.3 7.7
Hypercholesterolemia 30.8 7.7 5.1
Hypophosphatemia 28.2 2.6 0
Hypertriglyceridemia 25.6 25.6 5.1
Thrombocytopenia 61.5 30.8 7.7
Anemia 30.8 0 0
Nonhematologic adverse events
Anorexia 38.5 0 0
Nausea 35.9 2.6 0
Diarrhea 23.1 7.7 0
Rash 17.9 7.7 0
Stomatitis 10.3 20.5 0
vomiting 7.7 15.4 0
Pneumonitis 5.1 25.6 17.9Cancer Management and Research 2010:2 66
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illness, and 11 were too early for evaluation. 90% of patients 
who completed 8 weeks of treatment had objective response 
(21%) or minor response/stable disease (69%). There was a 
23% partial response rate in group A and 11% in group B, 
with 10% patients in group A and 44% in group B having 
stable disease. Median PFS was 9 months in group A and 
6 months in group B.39
Safety data from this study reported grade 3 or 4 
proteinuria occurred in 19% of patients, fatigue in 9% and 
stomatitis in 8% of patients. Grade 1 or 2 toxicities were 
common and included fatigue (68%), skin rash/pruritis 
(55%), mucositis/stomatitis (49%), hyperlipidemia (45%), 
nausea (40%) and hypertension (25%). The majority of 
side effects reversed quickly after stopping the treatment. 
Pneumonitis was also reversible if identified early. The 
group concluded that the combination of bevacizumab and 
everolimus is active and tolerable, with the combination 
working in patients previously treated with sorafenib and/or 
sunitinib.39
Phase III studies
The only Phase III study to date is by the RECORD-1 
study group who conducted a multicenter, randomized, 
double-blind, placebo-controlled trial of everolimus in 
patients with metastatic clear cell renal carcinoma whose 
disease had progressed on vascular endothelial growth 
factor-targeted therapy.40 Patients with metastatic renal cell 
carcinoma who had progressed on sunitinib, sorafenib, or 
both, were recruited from 86 centers in Australia, Canada, 
Europe, Japan and the USA. 554 patients were screened 
of whom 410 patients were randomly assigned in a 2:1 
ratio to receive everolimus 10 mg once daily (n = 272) 
or placebo (n = 138), in conjunction with best supportive 
care. 193 (71%) patients in the everolimus group and 109 
(79%) in the placebo group had progressed while receiving 
previous therapy.
Efficacy data
The primary end point was PFS, assessed by a blinded 
independent central review. The study was designed to be 
terminated after 290 events of progression. Analysis was by 
intention to treat. The results of the second interim analysis 
indicated a significant difference in efficacy between arms 
and the trial was thus halted early after 191 progression events 
had been observed (101 [37%] events in the everolimus 
group, 90 [65%] in the placebo group; hazard ratio 0.30.95% 
CI 0.22 to 0.40, P  0001). Median PFS was 4.0 [95% CI 
3.7 to 5.5] vs 1.9 [1.8 to 1.9] months).
The study raised some important questions about the 
increasing difficulty in detecting improvements in overall 
survival in confirmatory phase III studies with the advent of 
ever increasingly effective second and third-line therapies, 
and the growing use of cross-over design.
Safety data
This study reported the adverse events shown in Table 2.
The group reported that most adverse events noted in both 
arms were grade 1 or 2. Those that occurred more frequently 
in the everolimus group than placebo group were stomatitis, 
rash, fatigue and diarrhea. Patients in the everolimus arm had 
higher rates of grade 3 or 4 stomatitis, infections, and non-
infectious pneumonitis than did those in the placebo group. 
Of the 8 patients with grade 3 pneumonitis, 6 discontinued 
everolimus therapy. Four showed complete clinical resolution, 
and three showed improvement to grade 2 or less. Grade 3 or 4 
lymphopenia, grade 3 hyperglycemia, grade 3 hypophospha-
temia, and grade 3 hypercholesterolemia occurred more often 
in patients receiving everolimus than in those administered 
placebo. The majority of cases of hyperglycemia occurred 
in patients who had an abnormal fasting glucose level before 
taking everolimus and optimal glycemic control before start-
ing a patient on everolimus has been recommended.41
Study drug toxicity led to treatment discontinuation for 
28 (10%) patients receiving everolimus (with pneumonitis, 
dyspnea and fatigue being the most common reasons) and 
for 5 (4%) patients in the placebo group. 92 (34%) patients 
in the everolimus group and 20 (15%) in the placebo group 
required a dose interruption, whereas 14 (5%) in the evero-
limus group and one (1%) in the placebo group had a dose 
reduction with no preceding interruption.
The group reported the death of 14 (5%) patients in the 
everolimus group and 6 (4%) in the placebo group within 28 
days of their last dose (all causes); one patient in the evero-
limus group died from overwhelming candidal sepsis com-
plicated by acute respiratory failure, which they felt might 
have been attributable to the study drug. One patient receiving 
placebo died from a myocardial infarction, with all of the 
remaining deaths attributed to underlying malignancy.40
everolimus and pneumonitis
Non-infectious pneumonitis, a potentially serious adverse 
event associated with rapamycin and rapamycin derivative 
treatment is also seen with everolimus. It comprises one of a 
number of typical radiographic appearances with or without 
symptoms (dry cough, breathlessness, malaise) and signs 
(pleural effusion, crepitations, hypoxemia) in the absence Cancer Management and Research 2010:2 67
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of a non-drug cause.41 The Phase II study discussed earlier 
reported grade 1 or 2 pneumonitis in 31% of patients. Grade 3 
pneumonitis occurred in 19% of patients which resolved with 
dose delays and dose reductions. None of the patients required 
steroids and the pneumonitis resolved with the cessation of 
the drug.38 In the Phase III study, grade 3 pneumonitis was 
reported in 3% of the patients. The group planned on a detailed 
analysis of the clinical and radiological features which may 
provide more insight into the mechanism of causation. As with 
any novel therapy, the diagnosis and management of toxicity 
changes and develops with time and experience. This is the 
most likely explanation for the differences seen in pneumonitis 
between the Phase II and Phase III studies, as it cannot be 
explained in terms of different patient characteristics or pre-
vious therapy. The drug company recommendations on the 
management of non-infections pneumonitis (see Table 4).
Patient-focused outcomes including 
quality of life and satisfaction
The RECORD-1 study assessed health-related quality-of-
life with the European Organization for the Research and 
Treatment of Cancer (EORTC) QLQ-30 and Functional 
assessment of cancer therapy Kidney Symptom Index-
Disease related symptoms (FKSI-DRS) questionnaires. These 
Table 2 Adverse events in percentages
Cohorts Everolimus group  
(n = 269)
Placebo group  
(n = 135)
Significant difference 
between groups
Grades All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 P value
Adverse events
Stomatitis 40 3 0 8 0 0 0.03
Rash 25 1 0 4 0 0
Fatigue 20 3 0 16 1 0
Asthenia 18 1 0 8 1 0
Diarrhea 17 1 0 3 0 0
Anorexia 16 1 0 6 0 0
Nausea 15 0 0 8 0 0
Mucosal inflammation 14 1 0 2 0 0
vomiting 12 0 0 4 0 0
Cough 12 0 0 4 0 0
Dry skin 11 1 0 4 0 0
infections 10 2 1 2 0 0 0.03
Pneumonitis 8 3 0 0 0 0
Dyspnea 8 1 0 2 0 0
Laboratory abnormalities
Anemia 91 9 1 76 5 0
Hypercholesterolemia 76 3 0 32 0 0 0.03
Hypertriglyceridemia 71 1 0 30 0 0
Hyperglycemia 50 12 0 23 1 0 0.0001
Raised creatinine 46 1 0 33 0 0
Lymphopenia 42  14 1 29 5 0 0.002
Raised alkaline  
phosphatase
37 1 0 30 1 0
Hypophospatemia 32 4 0 7 0 0 0.01
Leucopenia 26 0 0 8 0 1
Raised aspartate  
aminotransferase
21 1 0 7 0 0
Thrombocytopenia 20 1 0 2 0 1
Raised alanine  
aminotransferase
18 1 0 4 0 0
Hypocalcemia 17 0 0 6 0 0
Neutropenia 11 0 0 3 0 0Cancer Management and Research 2010:2 68
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Table 3 Management of noninfectious pneumonitis41
Severity Recommended investigations Management Everolimus dose adjustment
Grade 1:   Asymptomatic; clinical  
or diagnostic observations only;  
intervention not indicated
CT scans with lung windows and  
pulmonary function testinga Repeat  
a chest X-ray/CT scan every  
2 cycles until return to baseline.
No specific therapy  
is required
Adminster 100% of the dose
Grade 2: Symptomatic; medical  
intervention indicated; limiting  
instrumental ADL
CT scan with lung windows  
and pulmonary function testinga  
Repeat each subsequent cycle  
until return to baseline. 
Consider bronchoscopya
Symptomatic only.  
Corticosteroids if cough  
is troublesome
Reduce dose until recovery to grade  
1. everolimus may also be interrupted 
if symptoms are troublesome. 
Discontinue treatment if patient fails to 
recover to grade 1 within 3 weeks
Grade 3: Severe symptoms;  
limiting self care ADL;  
oxygen indicated
CT scan with lung windows  
and pulmonary function testing.a 
Repeat each subsequent cycle  
until return to baseline.  
Bronchoscopya is required
Prescribe corticosteroids  
if infective origin is ruled  
out.   Taper as medically  
indicated
Hold treatment until recovery to grade 
1. May restart everolimus within 
2 weeks at a reduced dose (by one 
level) if evidence of clinical benefit
Grade 4: Life-threatening  
respiratory compromise; urgent  
intervention indicated  
(eg, tracheotomy or intubation
CT scan with lung windows and  
pulmonary function testing.b 
Repeat each subsequent cycle until  
return to baseline. Bronchoscopyb  
is required
Prescribe corticosteroids  
if infective origin is ruled  
out.   Taper as medically  
indicated
Discontinue treatment
aPulmonary function test includes spirometry, carbon monoxide diffusion capacity (DLCO), and room air oxygen saturation at rest.
bBronchoscopy to include biopsy and/or bronchoalveolar lavage.
Abbreviation: ADL, activities of daily living.
Table 4 www.clinicaltrials.gov42
Phase/sites Monotherapy/ 
combination drugs
Histological type Outcome measures NCT ID
Phase ii (ReCORD-3),  
multicenter
everolimus followed by  
Sunitinib vs Sunitinib  
followed by everolimus
All sub-types Efficacy and safety data NCT00903175
Phase ii everolimus and  
bevacizumab
Treatment refractory  
predominantly clear cell  
or predominantly  
sarcomatoid features
Progression free survival NCT00651482
Phase i/ii  
Single group assignment
everolimus and  
sorafenib
Clear cell renal cancer Maximum tolerated dose  
and objective response rate
NCT00384969
Phase ii, multicenter  
(RAPTOR)
Monotherapy Metastatic papillary  
cell cancer
Efficacy-defined as the  
percentage of patients  
progression-free at 6 months
NCT00688753
Phase ii Monotherapy Non-clear cell renal cell  
carcinoma
Progression free survival NCT00830895
were administered before randomization, on the first day of 
each cycle, and on discontinuation from the study.
No significant differences were evident between the 
everolimus group and the placebo group in the time to 
definitive deterioration of patient-reported outcomes, as 
determined by pre-established criteria for clinically mean-
ingful changes (EORTC QLQ-C30:physical functioning 
scale hazard ratio 0.94, 95% CI 0.64 to 1.39; global health 
status/quality of life score 1.02, 0.70 to 1.50; FKSI-DRS 
risk score:0.82, 0.57 to 1.18). Longitudinal mean scores 
for the FKSI-DRS and the global health status/quality of 
life, physical, role functioning, emotional, cognitive and 
social functioning, and symptoms scales of the EORTC 
QLQ-C30 questionnaire indicated that quality of life was 
sustained during treatment with everolimus relative to 
placebo. This was irrespective of the adverse effects that 
might be expected from the toxicities associated with an 
active treatment. There was therefore no detrimental effect 
on health-related quality of life for everolimus compared 
with placebo in this study.41Cancer Management and Research 2010:2 69
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Ongoing clinical trials
Conclusion
Understanding of the biology of advanced RCC and the 
approval of several drugs for treatment has now meant that 
there are logical ways of combining the many therapeutic 
options for this disease. There is growing evidence that 
administering targeted therapies sequentially provides clini-
cal benefit by inducing tumor shrinkage and prolonged PFS. 
By using these drugs sequentially, one can expect to increase 
PFS of up to 27 months.43 Everolimus may become standard 
second or third line therapy in patients who have progressive 
disease on or after first-line therapy with multi-kinase inhibi-
tors or VEGF inhibitors, especially given its minimal effect on 
patients’ quality of life. Careful patient selection and monitor-
ing of therapy, including surrogate/predictive biomarkers is 
essential. Although the stability of certain phosphoproteins, 
in particular phospho-Akt, has been called into question, 
phosphor-S6 appears to be a promising potential predictive 
biomarker for assessing response to mTOR inhibitors, which 
may be validated through both larger retrospective analysis 
and prospective studies.44
There have been recent studies suggesting that HIF-2α 
expression, which is dependent on mTORC2 is critical 
in RCC tumorigenesis. This could mean that targeting 
rapamycin-insensitive mTORC2, which lies upstream 
of AKT25 could prove to be important in patients who 
develop resistance whilst on everolimus therapy. Another 
mechanism of resistance involves increased insulin growth 
factor-1 receptor (IGF-1R)/PI3K/AKT signaling as a 
result of loss of mTOR/S6K inhibition whilst on therapy 
which limits the antitumor effect of mTOR inhibitors. 
Combined therapy with IGF-1R inhibitors or inhibitors 
of PI3K and AKT may therefore be useful.45–47 More 
studies looking into the mechanisms of resistance to these 
compounds need to be done as our experience with this 
agent increases.
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